You are here

  • Home
  • Archive
  • Volume 9, Issue 4
  • Correction: The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis

https://doi.org/10.1136/rmdopen-2023-003317corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Kivitz A, Wang L, Alevizos I, et al. The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis. RMD Open 2023;9:e003317. doi: 10.1136/rmdopen-2023-003317

    In this article, Figure 4 has been updated to resolve an error.